Spatial heterogeneity challenges limited sampling of claudin 18 expression in cholangiocarcinoma

Abstract Background Claudin 18.2 (CLDN18.2) has emerged as a therapeutic target in gastrointestinal cancers, and CLDN18-directed strategies are entering trials in cholangiocarcinoma. Because biomarker classification may depend on the proportion of tumor cells with moderate-to-strong staining, spatial heterogeneity could affect assessment from limited tissue. We aimed to characterize intratumoral heterogeneity of CLDN18 immunohistochemical expression in cholangiocarcinoma. Methods We analysed 85 whole-section blocks from 38 patients in a selected, CLDN18-enriched cohort derived from a previously published cholangiocarcinoma series. CLDN18 expression was quantified as the percentage of tumor cells with moderate-to-strong (2+/3+) membranous staining and classified at a ≥ 75% threshold. Spatial expression patterns were annotated, and patient-level whole-section classifications were compared with prior tissue-microarray results. Results At patient level, 11 of 38 cases were uniformly above the ≥ 75% threshold across evaluated blocks, 4 were heterogeneous, and 23 were uniformly below threshold. Among patients with at least two assessable blocks, interblock heterogeneity was observed in 4 of 29 cases (13.8%). Overall, 29 of 85 blocks (34.1%) met the ≥ 75% threshold. Tissue-microarray and whole-section classifications agreed in 30 of 38 patients (78.9%; κ = 0.57). Independent reassessment showed high agreement for block-level threshold classification (92.9%; κ = 0.85), while spatial-pattern assignment showed substantial agreement (81.2%; κ = 0.67). Conclusions In this selected cohort enriched for tumors with prior partial or strong CLDN18 expression, staining was consistent across sampled blocks in most cases, while 4 of 29 multiblock cases crossed the ≥ 75% threshold between blocks. A single TMA core, used here as a model of limited tissue sampling, did not always reflect the broader whole-section classification. These findings identify sampling heterogeneity as a practical consideration for CLDN18 assessment in CCA and suggest that spatial pattern may provide useful context alongside percentage staining.

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2026-11-16
DOI
https://doi.org/10.1186/s12885-026-17319-x
Primary Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Spatial heterogeneity challenges limited sampling of claudin 18 expression in cholangiocarcinoma

Dirk Walter, Lukas Haug, Aayushi Srivastava, Julia Bein et al.
8 links
BMC Cancer
Cholangiocarcinoma and Gallbladder Cancer Studies
article

Spatial heterogeneity challenges limited sampling of claudin 18 expression in cholangiocarcinoma

Dirk Walter, Lukas Haug, Aayushi Srivastava, Julia Bein, Armin Wiegering, PJ Wild, Maximilian N. Kinzler, Ole Beldermann, Stefan Zeuzem
article en

Abstract

Abstract Background Claudin 18.2 (CLDN18.2) has emerged as a therapeutic target in gastrointestinal cancers, and CLDN18-directed strategies are entering trials in cholangiocarcinoma. Because biomarker classification may depend on the proportion of tumor cells with moderate-to-strong staining, spatial heterogeneity could affect assessment from limited tissue. We aimed to characterize intratumoral heterogeneity of CLDN18 immunohistochemical expression in cholangiocarcinoma. Methods We analysed 85 whole-section blocks from 38 patients in a selected, CLDN18-enriched cohort derived from a previously published cholangiocarcinoma series. CLDN18 expression was quantified as the percentage of tumor cells with moderate-to-strong (2+/3+) membranous staining and classified at a ≥ 75% threshold. Spatial expression patterns were annotated, and patient-level whole-section classifications were compared with prior tissue-microarray results. Results At patient level, 11 of 38 cases were uniformly above the ≥ 75% threshold across evaluated blocks, 4 were heterogeneous, and 23 were uniformly below threshold. Among patients with at least two assessable blocks, interblock heterogeneity was observed in 4 of 29 cases (13.8%). Overall, 29 of 85 blocks (34.1%) met the ≥ 75% threshold. Tissue-microarray and whole-section classifications agreed in 30 of 38 patients (78.9%; κ = 0.57). Independent reassessment showed high agreement for block-level threshold classification (92.9%; κ = 0.85), while spatial-pattern assignment showed substantial agreement (81.2%; κ = 0.67). Conclusions In this selected cohort enriched for tumors with prior partial or strong CLDN18 expression, staining was consistent across sampled blocks in most cases, while 4 of 29 multiblock cases crossed the ≥ 75% threshold between blocks. A single TMA core, used here as a model of limited tissue sampling, did not always reflect the broader whole-section classification. These findings identify sampling heterogeneity as a practical consideration for CLDN18 assessment in CCA and suggest that spatial pattern may provide useful context alongside percentage staining.

BMC Cancer
Goethe University Frankfurt (DE), Frankfurt Institute for Advanced Studies (DE), University Hospital Frankfurt (DE), Frankfurt Cancer Institute (DE)
Good health and well-being
Cholangiocarcinoma and Gallbladder Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon